NLS Pharmaceutics
NLSP
NLSP
7 hedge funds and large institutions have $9.62M invested in NLS Pharmaceutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
7
Holders Change
+2
Holders Change %
+40%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
Top Sellers
| 1 |
1
UBS Group
Zurich,
Switzerland
|
$0 |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
BI
1
BVF Inc
San Francisco,
California
| $8.68M | – | – | – |
|
|
AAA
2
Affinity Asset Advisors
New York
| $520K | +$520K | +8,602 | New |
|
|
JGC
3
J. Goldman & Co
New York
| $311K | +$311K | +5,119 | New |
|
4
Renaissance Technologies
New York
| $49K | +$18.2K | +298 | +59% |
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $35.4K | +$35.4K | +586 | New |
|
6
Geode Capital Management
Boston,
Massachusetts
| $21.7K | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $137 | +$137 | +2 | New |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$12.7K | -246 | Closed |
|